NCT03881488
Study of CTX-471 as a Monotherapy or in Combination With Pembrolizumab in Patients Post PD-1/PD-L1 Inhibitors in Metastatic or Locally Advanced Malignancies
Registry record
- Lead sponsor
- Compass Therapeutics
- Conditions
- Locally Advanced Solid Tumor; Metastatic Cancer; Non-small Cell Lung Cancer; Small Cell Lung Cancer; Mesothelioma
- Primary completion
- May 21, 2025Actual
- Completion
- Locked
- Start
- Locked
- Enrollment
- Locked
- Interventions
- Locked
- Study type
- Locked
- Results on the registry
- Locked
- Record last updated
- Locked
Enrollment, interventions, the start and completion dates and the change history are locked on 1 row here. Included with TrialScanner ($9.99 a month) and Signal8 Pro.
Unlock with TrialScannerRecorded changes
0 changes recorded for this trial. The history, with each previous value, is part of TrialScanner.
Tracking since Nov 12, 2026. Changes before that date are not known to TrialScanner.